<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03432416</url>
  </required_header>
  <id_info>
    <org_study_id>CCN012B</org_study_id>
    <nct_id>NCT03432416</nct_id>
  </id_info>
  <brief_title>Study of Efficacy, Cycle Control, and Safety of a NES-E2 Contraceptive Vaginal Ring</brief_title>
  <official_title>A Multicenter, Open-label Randomized Study on the Efficacy, Cycle Control and Safety of a Contraceptive Vaginal Ring Delivering a Daily Dose of Nestorone® and Estradiol (NES-E2 CVR).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Health Decisions</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Population Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Health Decisions</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a multi-site, open-label, randomized clinical trial. The investigators will
      randomize 300 eligible participants in a 1:1 ratio to two different treatment regimens that
      are to be followed when using a contraceptive vaginal ring delivering a daily dose of
      Nestorone® and estradiol (NES-E2 CVR).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total duration of the study for each participant is expected to be approximately
      13.5-15.5 months: including screening and enrollment (up to 8 weeks), 12 months of
      participation, and a post-removal follow up period removal of at least 17 days. After
      enrollment, subject visits occur at day 31, 92, 183, 274, and 364 with telephone calls at day
      60, 120, 150, 210, 240, 300, and 330. Subjects will use a home pregnancy test 17 days
      post-removal of the ring and will call the site report the result and for safety follow-up.
      Another phone call will be required after that if the subject chooses not to being a hormonal
      contraceptive; this call will occur at the time of the subject's first spontaneous menses.

      Subject recruitment is expected to begin Q1 (in the first quarter of) 2018 and is planned to
      continue through Q1 2019. However, if the enrollment rate declines, the enrollment period may
      be extended beyond this date. If this enrollment timeline is met, all subjects should finish
      active treatment by approximately the end of Q1 2020. The end of the study will occur when
      the last subject to be enrolled has completed her post-removal telephone call(s).

      Preliminary results of the study are expected to be available Q3 of 2020 based on the current
      study plan.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2018</start_date>
  <completion_date type="Anticipated">June 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy Rate</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in subjects' bleeding patterns for continuous vs cyclic use as compared to reported baseline bleeding patterns when the subjects were not on hormonal contraception using a bleeding questionnaire.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in bleeding patterns for continuous vs cyclic use using a bleeding diary.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, including serious adverse events</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of number of bleeding and spotting days per 30- and 90- day intervals using a bleeding diary.</measure>
    <time_frame>Every 30 and 90 days up to a total of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of cyclic versus continuous use adverse events.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of acceptability questionnaires.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in complete blood count (CBC) labs from study entry (baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting sodium from study entry (baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting potassium from study entry (baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting chloride from study entry (baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting HCO3/CO2 from study entry (baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting glucose from study entry (baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting creatinine from study entry (baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting blood urea nitrogen (BUN) from study entry (baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting calcium from study entry (baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting Gamma-glutamyl transferase or Gamma-glutamyl transpeptidase (GGTP) from study entry (baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting protein from study entry (baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting albumin from study entry (baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting total bilirubin from study entry (baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting direct bilirubin from study entry (baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting alkaline phosphatase (ALPH) from study entry (baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting Alanine Aminotransferase (ALT) from study entry (baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fasting Aspartate Aminotransferase (AST) from study entry (baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in total cholesterol from study entry (baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in triglycerides from study entry (baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in high-density lipoprotein (HDL) from study entry (baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in low-density lipoprotein (LDL) from study entry (baseline)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Healthy Women</condition>
  <condition>Female Contraception</condition>
  <arm_group>
    <arm_group_label>Regimen 1: Continuous Usage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Contraceptive vaginal ring delivering a daily dose of Nestorone® and estradiol (NES-E2 CVR) worn continuously for 91 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 2: Cyclical Usage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Contraceptive vaginal ring delivering a daily dose of Nestorone® and estradiol (NES-E2 CVR) worn for 91 days, but is removed for 2 days each month (days 29-30, 59-60, and 90-91).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NES-E2 CVR</intervention_name>
    <description>NES-E2 CVR</description>
    <arm_group_label>Regimen 1: Continuous Usage</arm_group_label>
    <arm_group_label>Regimen 2: Cyclical Usage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Good general overall health with no chronic medical conditions that result in periodic
             exacerbations requiring significant medical care.

          2. Age 18-35 years, inclusive, at the enrollment visit. (Note: subjects must be at least
             18 years of age to provide consent.)

          3. Have a regular menstrual cycle 21-35 days in duration when not using hormonal
             contraception

          4. Have an intact uterus and at least one ovary.

          5. Consistent use of effective contraception during the preceding cycle with no
             unprotected intercourse since last use (NOTE: women who use oral, transdermal,
             vaginal, or implantable hormonal contraceptives in the preceding cycle must have
             discontinued hormone use at least 4 days prior to start of treatment and must not have
             had unprotected intercourse since discontinuing the method. Copper IUD or
             Levonorgestrel releasing IUD users must have discontinued IUD use at least 4 days
             prior to start of treatment and have experienced a spontaneous menses following IUD
             removal.)

          6. No use of injectable contraceptives (e.g. depomedroxyprogesterone acetate) during the
             10 months prior to screening unless the subject has returned to normal menses (two
             consecutive menses) since last injection.

          7. Have a negative pregnancy test at the enrollment visit.

          8. Have a diastolic blood pressure (BP) &lt;90 mm Hg and systolic BP &lt;140 mm Hg after 5
             minutes rest in sitting position at the admission visit (below hypertension stage 2).
             (Note: History of hypertension stage 2 or higher, even if controlled with treatment,
             is exclusionary.)

          9. Willing to abstain from use of non-water based (including silicone based) vaginal
             lubricants during the study that could adversely affect the ring, causing it to
             expand.

         10. Understand and sign an IRB-approved informed consent form prior to screening
             activities (including fasting blood draws).

         11. BMI ≤ 35 kg/m2 and not having previously undergone bariatric surgery.

         12. Planning to have at least one act of heterosexual intercourse without the use of
             another contraceptive method each month during study participation until end of
             treatment and at risk for pregnancy.

        Exclusion Criteria:

          1. Planning pregnancy during study participation through the end of treatment visit.

          2. Within 30 days post-partum, currently breast-feeding, or has not had a spontaneous
             menses.

          3. Post-abortal and has not had a spontaneous menses.

          4. Abnormal genital bleeding.

          5. Participating in another clinical trial involving an investigational product within
             the last 30 days (prior to screening) or planning to participate in another clinical
             trial during this study.

          6. Not living in the catchment area of the study site.

          7. Known hypersensitivity to progestins or estrogens.

          8. Contraindications to combined estrogen-progestin contraceptive use including:

               1. Thrombophlebitis or thromboembolic disorders.

               2. Personal history of deep vein thrombophlebitis or thromboembolic disorders.

               3. History of venous thrombosis or embolism in a first-degree relative &lt;55 years of
                  age suggesting a familial defect in the blood coagulation system.

               4. History of thrombosis or embolism OR any other personal or family history which
                  in the opinion of the investigator suggests increased risk.

               5. History of stroke.

               6. Known history of any of the following genetic mutations: Factor V Leiden
                  mutation, prothrombin mutation, antithrombin deficiency, or other clinically
                  significant thrombophilia.

               7. Known or suspected carcinoma of the breast.

               8. Carcinoma of the endometrium or other known or suspected estrogen-dependent
                  neoplasm.

               9. History of cholestatic jaundice of pregnancy or jaundice with prior hormonal
                  contraceptive use.

              10. History of hepatic adenomas or carcinomas.

              11. Known or suspected pregnancy.

              12. Smoking in women who are or will be 35 years during the course of the trial;
                  women &lt;35 years who smoke 15 cigarettes or more per day must be evaluated by the
                  investigator for inclusion based on risk factors that would increase their risk
                  for cardiovascular disease (CVD) and thromboembolism, e.g. lipid levels, glucose
                  level, BP, BMI, family history of CVD at a young age. Individuals who use other
                  forms of tobacco should be evaluated similarly by the investigator for inclusion
                  based on the amount of tobacco use and their risk factors.

              13. History of retinal vascular lesions, unexplained partial or complete loss of
                  vision.

              14. History of headaches with focal neurological symptoms (e.g., migraines with
                  auras).

              15. Impaired mobility (e.g. wheelchair bound, bed-ridden) that, in the opinion of the
                  investigator, places the woman at increased risk of thrombosis.

          9. Unevaluated vaginal discharge or vaginal lesions. Subjects diagnosed at screening with
             a chlamydia or gonococcal infection may be included in the trial following treatment
             completion; partner treatment is also recommended. Subjects with yeast,
             trichomoniasis, or bacterial vaginosis infection requiring treatment may be enrolled
             after treatment completion. Investigators should determine if subjects are at an
             elevated risk for reinfection, e.g. multiple sex partners, untreated partner, and
             whether such subjects can be included. Women with a history of genital herpes can be
             included if outbreaks are infrequent.

         10. Have a known clinically significant Pap test abnormality, as managed by normal
             standard of care guidelines, that would require repeat evaluation or treatment during
             study participation based on the initial Pap findings.

         11. Known benign or malignant liver tumors, renal disease or active liver disease.

         12. Invasive cancer (past history of any carcinoma or sarcoma, except non-melanoma skin
             cancer).

         13. Current or past medically diagnosed severe depression, which, in the opinion of the
             investigator, could be exacerbated by use of a hormonal contraceptive.

         14. Known or suspected current alcohol dependence, chronic marijuana use, or any illicit
             drug use that may affect metabolism/transformation of study product and/or study
             treatment compliance. A chronic marijuana user is defined as someone who uses
             marijuana 4 or more times per week for study purposes.

         15. Elevated fasting clinical chemistry values or complete blood count (CBC) values
             designated clinically significant by the investigator or medically qualified
             sub-investigator.

         16. Uncontrolled thyroid disease.

         17. Known impaired hypothalamic-pituitary-adrenal axis.

         18. Known hypersensitivity to silicone rubber.

         19. History of toxic shock syndrome.

         20. Vaginal anatomic abnormality such as cystocele or rectocele that would preclude
             correct use of a vaginal ring.

         21. Planning major surgery during study participation.

         22. Severe current constipation.

         23. Use of liver enzyme inducers or inhibitors on a regular basis.

         24. Known HIV infection.

         25. Use of any medications, including antibiotics that can significantly interfere with
             the metabolism of hormonal contraceptives.

         26. Have an anticipated need for regular condom use, defined as use of at least one condom
             per month after enrollment.

         27. Have issues or concerns (in the judgment of the investigator) that may compromise the
             safety of the subject or confound the reliability of compliance and information
             acquired in this study.

         28. Any site staff member with delegated study responsibilities or a family member of a
             site staff member with delegated study responsibilities.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Danielle Slovitz Jenkner</last_name>
    <phone>919-967-1111</phone>
    <phone_ext>151</phone_ext>
    <email>dslovitz@healthdec.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abbey Townsend</last_name>
    <phone>919-967-1111</phone>
    <phone_ext>308</phone_ext>
    <email>atownsend@healthdec.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Essential Access Health</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>30010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kieumai Vo</last_name>
      <phone>213-386-5614</phone>
      <phone_ext>4592</phone_ext>
      <email>KVo@essentialaccess.org</email>
    </contact>
    <contact_backup>
      <last_name>Ron Frezeries</last_name>
      <phone>213-386-5614</phone>
      <phone_ext>4403</phone_ext>
      <email>RFrezieres@essentialaccess.org</email>
    </contact_backup>
    <investigator>
      <last_name>Anita Nelson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Overstreet</last_name>
      <phone>916-734-6846</phone>
      <email>cboverstreet@ucdavis.edu</email>
    </contact>
    <contact_backup>
      <last_name>Aubrey Blanton</last_name>
      <phone>916-734-6846</phone>
      <email>akblanton@ucdavis.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mitchell Creinin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ines Crato</last_name>
      <phone>303-724-5559</phone>
      <email>INES.CRATO@UCDENVER.EDU</email>
    </contact>
    <contact_backup>
      <last_name>Rebecca Seale</last_name>
      <phone>303-724-2013</phone>
      <email>REBECCA.SEALE@UCDENVER.EDU</email>
    </contact_backup>
    <investigator>
      <last_name>Stephanie Teal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina Thaler</last_name>
      <phone>410-550-8506</phone>
      <email>kstouff3@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Beal</last_name>
      <phone>410-550-4825</phone>
      <email>lbeal2@jhu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Anne Burke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bellevue Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Davis</last_name>
      <phone>212-263-6253</phone>
      <email>anna.davis@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Treasure Walker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Subrina Bisnauth</last_name>
      <phone>212-305-8031</phone>
      <email>Snb2147@cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Connie Colon</last_name>
      <phone>212-305-6098</phone>
      <email>cc3238@cumc.columbia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Carolyn Westhoff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Boerschig</last_name>
      <phone>513-584-4100</phone>
      <email>BOERSCDA@UCMAIL.UC.EDU</email>
    </contact>
    <contact_backup>
      <last_name>Tiffany Rupert</last_name>
      <phone>513-584-4100</phone>
      <email>tiffany.rupert@uc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Thomas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariela Schnyer</last_name>
      <phone>503-494-3173</phone>
      <email>schnyer@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alison Edelman</last_name>
      <phone>503-494-5949</phone>
      <email>edelmana@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Jensen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania School of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Morley</last_name>
      <phone>215-615-4202</phone>
      <email>Andrea.morley@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kieran Alessi</last_name>
      <phone>215-615-3664</phone>
      <email>Kieran.Alessi@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kurt Barnhart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasmin Alcantra</last_name>
      <phone>801-213-3796</phone>
      <email>jasmin.alcantara@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amy Orr</last_name>
      <phone>801-213-2774</phone>
      <email>amy.orr@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David Turok</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical School</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Rocccazella</last_name>
      <phone>757-446-7161</phone>
      <email>roccazj@evms.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kim Pitts</last_name>
      <phone>757-446-8925</phone>
      <email>pittska@evms.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David Archer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Daulaire N, Leidl P, Mackin L et al., Promises to Keep: The Toll of Unintended Pregnancies on Women's Lives in the Developing World. Washington, DC: Global Health Council; 2002; 11.</citation>
  </reference>
  <reference>
    <citation>Speidel JJ, Harper CC, Shields WC. The potential of long-acting reversible contraception to decrease unintended pregnancy. Contraception. 2008 Sep;78(3):197-200. doi: 10.1016/j.contraception.2008.06.001. Epub 2008 Jul 9.</citation>
    <PMID>18692608</PMID>
  </reference>
  <reference>
    <citation>Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health. 2006 Jun;38(2):90-6.</citation>
    <PMID>16772190</PMID>
  </reference>
  <reference>
    <citation>Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update. 2006 Mar-Apr;12(2):169-78. Epub 2005 Nov 16. Review.</citation>
    <PMID>16291771</PMID>
  </reference>
  <reference>
    <citation>Sitruk-Ware R. Pharmacological profile of progestins. Maturitas. 2008 Sep-Oct;61(1-2):151-7.</citation>
    <PMID>19434887</PMID>
  </reference>
  <reference>
    <citation>Heikinheimo O, Ranta S, Moo-Young A, Lähteenmäki P, Gordon K. Parenteral administration of progestin Nestorone to lactating cynomolgus monkeys: an ideal hormonal contraceptive at lactation? Hum Reprod. 1999 Aug;14(8):1993-7.</citation>
    <PMID>10438416</PMID>
  </reference>
  <reference>
    <citation>Heikinheimo O, Noe G, Haukkamaa M, Lähteenmäki P. The progestin ST 1435--rapid metabolism in man. Contraception. 1994 Sep;50(3):275-89.</citation>
    <PMID>7805378</PMID>
  </reference>
  <reference>
    <citation>Kumar N, Koide SS, Tsong Y, Sundaram K. Nestorone: a progestin with a unique pharmacological profile. Steroids. 2000 Oct-Nov;65(10-11):629-36.</citation>
    <PMID>11108869</PMID>
  </reference>
  <reference>
    <citation>Kumar N, Fagart J, Liere P, Mitchell SJ, Knibb AR, Petit-Topin I, Rame M, El-Etr M, Schumacher M, Lambert JJ, Rafestin-Oblin ME, Sitruk-Ware R. Nestorone® as a Novel Progestin for Nonoral Contraception: Structure-Activity Relationships and Brain Metabolism Studies. Endocrinology. 2017 Jan 1;158(1):170-182. doi: 10.1210/en.2016-1426.</citation>
    <PMID>27824503</PMID>
  </reference>
  <reference>
    <citation>Haukkamaa M, Laurikka-Routti M, Heikinheimo O, Moo-Young A. Contraception with subdermal implants releasing the progestin ST-1435: a dose-finding study. Contraception. 1992 Jan;45(1):49-55.</citation>
    <PMID>1591921</PMID>
  </reference>
  <reference>
    <citation>Fraser IS, Weisberg E, Brache V, Alvarez F, Massai R, Mishell DR Jr, Apter D, Gale J, Tsong YY, Sivin I. Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen. Contraception. 2005 Jul;72(1):40-5.</citation>
    <PMID>15964291</PMID>
  </reference>
  <reference>
    <citation>Sivin I, Mishell DR Jr, Alvarez F, Brache V, Elomaa K, Lähteenmäki P, Massai R, Miranda P, Croxatto H, Dean C, Small M, Nash H, Jackanicz TM. Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial. Contraception. 2005 Feb;71(2):122-9.</citation>
    <PMID>15707562</PMID>
  </reference>
  <reference>
    <citation>Weisberg E, Brache V, Alvarez F, Massai R, Mishell DR Jr, Apter D, Gale J, Sivin I, Tsong YY, Fraser IS. Clinical performance and menstrual bleeding patterns with three dosage combinations of a Nestorone progestogen/ethinyl estradiol contraceptive vaginal ring used on a bleeding-signaled regimen. Contraception. 2005 Jul;72(1):46-52.</citation>
    <PMID>15964292</PMID>
  </reference>
  <reference>
    <citation>Rad M, Kluft C, Ménard J, Burggraaf J, de Kam ML, Meijer P, Sivin I, Sitruk-Ware RL. Comparative effects of a contraceptive vaginal ring delivering a nonandrogenic progestin and continuous ethinyl estradiol and a combined oral contraceptive containing levonorgestrel on hemostasis variables. Am J Obstet Gynecol. 2006 Jul;195(1):72-7. Epub 2006 Mar 20.</citation>
    <PMID>16545330</PMID>
  </reference>
  <reference>
    <citation>Kluft C, Meijer P, LaGuardia KD, Fisher AC. Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables. Contraception. 2008 Feb;77(2):77-83. doi: 10.1016/j.contraception.2007.10.004. Epub 2008 Jan 11.</citation>
    <PMID>18226669</PMID>
  </reference>
  <reference>
    <citation>Mashchak CA, Lobo RA, Dozono-Takano R, Eggena P, Nakamura RM, Brenner PF, Mishell DR Jr. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol. 1982 Nov 1;144(5):511-8.</citation>
    <PMID>6291391</PMID>
  </reference>
  <reference>
    <citation>Marty JP, James M, Hajo N, Wepierre J Percutaneous absorption of oestradiol and progesterone: Pharmacokinetic studies. In P Mauvais-Jarvis, CFH Vickers, J Wepierre (Eds), Percutaneous absorption of steroids. London: Academic Press Inc. (London) Ltd. 1980.</citation>
  </reference>
  <reference>
    <citation>Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet. 2000 Sep;39(3):233-42.</citation>
    <PMID>11020137</PMID>
  </reference>
  <reference>
    <citation>Jensen JT, Burke AE, Barnhart KT, Tillotson C, Messerle-Forbes M, Peters D. Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis. Contraception. 2008 Dec;78(6):451-8. doi: 10.1016/j.contraception.2008.07.004. Epub 2008 Aug 28.</citation>
    <PMID>19014790</PMID>
  </reference>
  <reference>
    <citation>Sitruk-Ware R, Plu-Bureau G, Menard J, Conard J, Kumar S, Thalabard JC, Tokay B, Bouchard P. Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. J Clin Endocrinol Metab. 2007 Jun;92(6):2074-9. Epub 2007 Mar 20.</citation>
    <PMID>17374706</PMID>
  </reference>
  <reference>
    <citation>Brache V, Mishell DR, Lahteenmaki P, Alvarez F, Elomaa K, Jackanicz T, Faundes A. Ovarian function during use of vaginal rings delivering three different doses of Nestorone. Contraception. 2001 May;63(5):257-61.</citation>
    <PMID>11448466</PMID>
  </reference>
  <reference>
    <citation>Odlind V, Lithell H, Selinus I, Vessby B. Unaltered lipoprotein and carbohydrate metabolism during treatment with contraceptive subdermal implants containing ST-1435. Ups J Med Sci. 1984;89(2):151-8.</citation>
    <PMID>6380075</PMID>
  </reference>
  <reference>
    <citation>Goebelsmann U, Mashchak CA, Mishell DR Jr. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am J Obstet Gynecol. 1985 Apr 1;151(7):868-77.</citation>
    <PMID>3920910</PMID>
  </reference>
  <reference>
    <citation>Protocol 330. Clinical Study Report on File. Population Council, New York, NY.</citation>
  </reference>
  <reference>
    <citation>Archer DF, Jensen JT, Johnson JV, Borisute H, Grubb GS, Constantine GD. Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results. Contraception. 2006 Dec;74(6):439-45. Epub 2006 Sep 18.</citation>
    <PMID>17157099</PMID>
  </reference>
  <reference>
    <citation>Scarabin PY, Oger E, Plu-Bureau G; EStrogen and THromboEmbolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003 Aug 9;362(9382):428-32.</citation>
    <PMID>12927428</PMID>
  </reference>
  <reference>
    <citation>Belsey EM, Machin D, d'Arcangues C. The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Contraception. 1986 Sep;34(3):253-60.</citation>
    <PMID>3539509</PMID>
  </reference>
  <reference>
    <citation>Merkatz RB, Plagianos M, Hoskin E, Cooney M, Hewett PC, Mensch BS. Acceptability of the Nestorone®/ethinyl estradiol contraceptive vaginal ring: development of a model; implications for introduction. Contraception. 2014 Nov;90(5):514-21. doi: 10.1016/j.contraception.2014.05.015. Epub 2014 Jun 2.</citation>
    <PMID>24993487</PMID>
  </reference>
  <reference>
    <citation>Isidori AM, Pozza C, Esposito K, Giugliano D, Morano S, Vignozzi L, Corona G, Lenzi A, Jannini EA. Development and validation of a 6-item version of the female sexual function index (FSFI) as a diagnostic tool for female sexual dysfunction. J Sex Med. 2010 Mar;7(3):1139-46. doi: 10.1111/j.1743-6109.2009.01635.x. Epub 2009 Dec 1.</citation>
    <PMID>19968774</PMID>
  </reference>
  <reference>
    <citation>Borch KH, Braekkan SK, Mathiesen EB, Njølstad I, Wilsgaard T, Størmer J, Hansen JB. Anthropometric measures of obesity and risk of venous thromboembolism: the Tromso study. Arterioscler Thromb Vasc Biol. 2010 Jan;30(1):121-7. doi: 10.1161/ATVBAHA.109.188920. Epub 2009 Oct 15.</citation>
    <PMID>19834110</PMID>
  </reference>
  <reference>
    <citation>Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol. 2007 Oct;139(2):289-96.</citation>
    <PMID>17897305</PMID>
  </reference>
  <reference>
    <citation>Simmons KB, Kumar N, Plagianos M, Roberts K, Hoskin E, Han L, Alami M, Creasy G, Variano B, Merkatz R. Effects of concurrent vaginal miconazole treatment on the absorption and exposure of Nestorone® (segesterone acetate) and ethinyl estradiol delivered from a contraceptive vaginal ring: a randomized, crossover drug-drug interaction study. Contraception. 2018 Mar;97(3):270-276. doi: 10.1016/j.contraception.2017.10.010. Epub 2017 Oct 31.</citation>
    <PMID>29097225</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2018</study_first_submitted>
  <study_first_submitted_qc>February 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 14, 2018</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Women</keyword>
  <keyword>Female Contraception</keyword>
  <keyword>Vaginal Ring</keyword>
  <keyword>Contraceptive Vaginal Ring</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>ST 1435</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

